These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31416982)

  • 1. Neutralising antibodies to interferon-beta therapy in relapsing multiple sclerosis: a pilot study.
    Lau AYL; Chan E; Lau KK; Mok V; Siu DYW; Lee R
    Hong Kong Med J; 2019 Aug; 25 Suppl 5(4):22-25. PubMed ID: 31416982
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox.
    Sørensen PS
    Mult Scler; 2012 Feb; 18(2):131-2. PubMed ID: 22312007
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
    Sørensen S; Koch-Henriksen NJ; Pedersen CR; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E;
    Ugeskr Laeger; 2004 Oct; 166(41):3606-9. PubMed ID: 15515467
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
    Sorensen PS; Ross C; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E; Koch-Henriksen N;
    Lancet; 2003 Oct; 362(9391):1184-91. PubMed ID: 14568740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
    Bojar M; Zajac M; Meluzínová E; Houžvičková E; Libertinová J; Lišková P; Mat'oška V; Nyč O; Mináriková M
    Mult Scler; 2010 Dec; 16(12):1529-30; author reply 1531-2. PubMed ID: 20829243
    [No Abstract]   [Full Text] [Related]  

  • 6. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis.
    Deisenhammer F; Giovannoni G
    Mult Scler; 2004 Dec; 10(6):713-4; author reply 715. PubMed ID: 15584500
    [No Abstract]   [Full Text] [Related]  

  • 7. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
    Farrell RA; Giovannoni G
    Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
    Cludts I; Meager A; Thorpe R; Wadhwa M
    J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
    Polman C; Schellekens H; Killestein J
    Mult Scler; 2006 Jun; 12(3):245-6. PubMed ID: 16764335
    [No Abstract]   [Full Text] [Related]  

  • 10. Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis.
    Foley P; Reilly P; Coulson A; O'Riordan JI
    J R Coll Physicians Edinb; 2010 Jun; 40(2):105-10. PubMed ID: 21125049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
    McKay F; Schibeci S; Heard R; Stewart G; Booth D
    J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations.
    Scagnolari C; Bellomi F; Turriziani O; Bagnato F; Tomassini V; Lavolpe V; Ruggieri M; Bruschi F; Meucci G; Dicuonzo G; Antonelli G
    J Interferon Cytokine Res; 2002 Feb; 22(2):207-13. PubMed ID: 11911803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis?
    Rudge P
    Mult Scler; 2004 Apr; 10(2):123-5. PubMed ID: 15124755
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS.
    van der Voort LF; Vennegoor A; Visser A; Knol DL; Uitdehaag BM; Barkhof F; Oudejans CB; Polman CH; Killestein J
    Neurology; 2010 Oct; 75(14):1228-33. PubMed ID: 20921509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study.
    Paolicelli D; Manni A; Iaffaldano A; Di Lecce V; D'Onghia M; Iaffaldano P; Trojano M
    Eur J Clin Pharmacol; 2016 Aug; 72(8):1025-9. PubMed ID: 27251359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to IFN-beta: the Danish National IFN-beta Project.
    Sorensen PS; Ross C; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E; Koch-Henriksen N; ;
    Neurology; 2003 Nov; 61(9 Suppl 5):S27-8. PubMed ID: 14610108
    [No Abstract]   [Full Text] [Related]  

  • 20. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
    Koch-Henriksen N; Sørensen PS
    Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.